Navigation Links
Stereotaxis Announces Second Quarter 2010 Earnings Release Date and Conference Call
Date:7/9/2010

ST. LOUIS, July 9 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) announced today that it will release its financial results for the second quarter ended June 30, 2010, on Monday, August 2, 2010 after the close of the market. The Company will host a conference call and webcast on Monday, August 2, 2010 at 4:30 p.m. Eastern Time to discuss the Company's second quarter results and current corporate developments. Management is conducting the call earlier than its historical practice due to schedule conflicts.  The dial-in number for the conference call is 1-877-941-9205 for domestic participants and 1-480-629-9835 for international participants.

A taped replay of the conference call will also be available beginning approximately one hour after the call's conclusion and will be available for seven days.  This replay can be accessed by dialing 1-800-406-7325 for domestic callers and 303-590-3030 for international callers, both using passcode 4329312#.  The call will also be available on the Internet live and 90 days thereafter at the following URL:

http://www.videonewswire.com/event.asp?id=70601

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. Stereotaxis' Odyssey™ solutions integrate and manage information from disparate information sources, eliminating the challenge of interacting simultaneously with many separate diagnostic systems, driving optimized workflow and improved productivity.  The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. New Data Demonstrate Safety, Efficacy of Stereotaxis for Patients with AFIB, VT and Congenital Defects
2. Stereotaxis and Siemens Promote Integrated Odyssey(TM) Solutions
3. Stereotaxis Announces Vdrive(TM), a New Technology for Remote Navigation of Diagnostic Devices
4. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
5. Stereotaxis Installs First System in Taiwan
6. Stereotaxis System Procedure Featured on NBCs The TODAY Show
7. Stereotaxis is Notified of the FDA Approval of an Additional Magnetic Irrigated Catheter
8. Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter
9. Stereotaxis Announces Underwriters Exercise of Over-Allotment Option
10. Stereotaxis Announces Pricing of $26 Million Common Stock Offering
11. Stereotaxis Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... Back Pain ... and back pain with a reputable physician in their area, announces the launch of ... patient information for patients who are looking for reputable physicians to help them with ...
(Date:4/25/2017)... ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest ... chronic problems, I focus on preventative care with all my patients to alleviate possible future ... always feel free to contact my office and my trained staff will assist you in ...
(Date:4/25/2017)... ... , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will ... set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is ... of Medicine. He also serves as Medical Director for the Bureau of Emergency Medical ...
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... ... April 24, 2017 , ... Emmanuel College is introducing ... advance their careers. Beginning in the fall of 2017, Emmanuel’s program will allow registered ... few as 16 months and for as little as $14,528. These changes will enable ...
Breaking Medicine News(10 mins):